


BEST AVAILABLE COPY



PTO/SB/92 (01-03)
Approved for use through 11/30/2005. OMB 0591-0055
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY and APPOINTMENT OF NEW POWER OF ATTORNEY	Application Number	09/355,622
	Filing Date	09/23/99
	First Named Inventor	Dieter Soli
	Art Unit	1646
	Examiner Name	Mark Navarro
Attorney Docket Number		

I hereby revoke all previous powers of attorney given in the above-identified application:

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners at Customer Number

07276

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with Customer Number:

07276

OR

☐ Firm or Individual Name **DARBY & DARBY P.C.**
S. Peter Ludwig

Address **P.O. Box 5257**

City **New York**

Country **US**

State **NY**

Zip

10150-5257

Telephone **(212) 527-7700**

Fax **(212) 753-8237**

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/99)

SIGNATURE of Applicant or Assignee of Record

Name **Dieter Soli**

Signature *Dieter Soli*

Date **September 12, 2003**

Telephone

(212) 527-7770

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.


☐ Total of **1** forms are submitted.

Express Mail Label No.

Dated: _____

(M:38160200029-00000056376.DOC [REDACTED])

BEST AVAILABLE COPY



PTO/SB/86 (08-00)

Approved for use through 10/31/2002. CMB 0051-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Dieter Soll

Application No./Patent No.: 09/355,822 Filed/Issue Date: 09/23/99

Entitled: GLUTRINAL AMIDOTRANSFERASE - A NOVEL ESSENTIAL TRANSLATIONAL COMPONENT

Dieter Soll Individual
(Name of Assignee) Type of Assignee: e.g., corporation, partnership, university, government agency, etc.

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

In the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Dieter Soll To: Yale University
The document was recorded in the United States Patent and Trademark Office at Reel 010303, Frame 0807, or for which a copy thereof is attached.

2. From: Yale University To: Dieter Soll
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.05]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

09/12/2003
Date

Dieter Soll

Typed or printed name

Signature

Professor

Title

Express Mail Label No.

Date:

(M:381810200029-000100056374.DOC [REDACTED])

1

BEST AVAILABLE COPY

YALE UNIVERSITY

RELEASE TO INVENTOR
AND ASSIGNMENT OF RIGHT TO ROYALTIES

WHEREAS, Dieter Söll of Hamden, Connecticut (the "INVENTOR"), disclosed an invention entitled "GlutRNA^{Gln} Amidotransferase (AdT) - A Novel Essential Translation Component (Yale OCR 853)" as disclosed to the Office of Cooperative Research on January 13, 1997 (the "INVENTION"); and

WHEREAS, the said INVENTION was conceived and first reduced to practice under the auspices of Yale University, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut ("YALE"); and

WHEREAS, the rights of the INVENTORS and YALE in the invention are governed by the terms of the Yale University Patent Policy, as approved by the Yale Corporation in June of 1988 and revised in February of 1998; and

WHEREAS, pursuant to paragraph 3(a) of the Yale University Patent Policy, YALE has determined that it does not wish to participate in the licensing of the INVENTION, and that it is willing to release to the INVENTOR YALE's interest therein, subject to YALE retaining a non-exclusive royalty free license to use the INVENTION in its own research and subject to INVENTOR's agreement to assign to YALE the right to receive thirty (30) percent of net royalty or thirty (30) percent of any other consideration therefrom, regardless of form; and

WHEREAS, the Department of Health & Human Services has acquiesced in the proposed release, subject to the INVENTOR'S granting to the United States government a non-exclusive royalty-free license to use the invention, which license has been duly executed by the INVENTOR;

NOW, THEREFORE, in consideration of the mutual provisions of the Yale University Patent Policy and this agreement, the parties hereto do agree as follows:

1. YALE hereby retains a paid-up, non-exclusive, irrevocable license to practice the INVENTION described in the claims of the "PATENTS" (defined below) in its own research and for educational purposes and releases and transfers to the INVENTOR, and to his heirs, executors, administrators and assigns, all of its remaining rights and interest in and to the INVENTION and in and to any and all patents, whether United States or foreign, which at any time may be granted therefor, including any and all renewals, reissues and prolongations thereof (the "PATENTS").


2. The INVENTOR hereby assigns YALE thirty percent (30%) of all the net income received from the INVENTION. For purposes of this agreement, the term "net income received from the

NOT AVAILABLE

INVENTION" shall mean any and all amounts due or received by the INVENTOR or his heirs, executors, administrators or assignees (other than assignees who pay the INVENTOR fair value for the assignment) for or in consideration of the use, license, sublicense, sale, assignment or transfer of the INVENTION or any of the PATENTS, less legal expenses reasonably incurred through outside counsel by the INVENTOR in obtaining the PATENTS and in licensing, sublicensing, selling, assigning or transferring the INVENTION or the PATENTS. The INVENTOR agrees, on behalf of himself and his heirs, executors, administrators and assigns, to provide to YALE an annual report concerning the patenting, use, licensing, sublicensing, sale, transfer or assignment of the INVENTION and the PATENTS, the terms thereof and the amounts due the INVENTOR and YALE therefrom, and such other information as YALE may reasonably request from time to time.


IN WITNESS WHEREOF, this release and assignment has been duly executed by YALE and the INVENTOR as of the date set forth below.

Dieter Söll

Signature: 

Date: September 12, 2003

Yale University

By: 

E. Jonathan Soderstrom, Ph.D.

Managing Director, Office of Cooperative Research

Date: September 12, 2003